Financials in USD. Standardized financial statements.
A compact view of how Bellicum Pharmaceuticals, Inc. turns revenue into operating income and net income.
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $1.50M | $6.20M | $500,000 | $7.14M | $1.12M | $185,000 | $388,000 | $282,000 | $1.78M | $1.94M |
| Revenue Growth? | -75.8% | +1140.0% | -93.0% | +537.8% | +505.4% | -52.3% | +37.6% | -84.2% | -8.3% | 0.0% |
| Cost of Revenue? | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit? | $1.50M | $6.20M | $500,000 | $7.14M | $1.12M | $185,000 | $388,000 | $282,000 | $1.78M | $1.94M |
| Gross Margin? | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% |
| Operating Expenses? | $28.48M | $30.59M | $54.58M | $94.51M | $96.59M | $87.57M | $68.77M | $49.42M | $16.41M | $9.86M |
| Operating Income? | -$26.98M | -$24.87M | -$51.69M | -$87.36M | -$95.47M | -$87.39M | -$68.38M | -$49.13M | -$57.84M | -$7.92M |
| EBITDA? | -$26.98M | -$24.35M | $2.39M | -$87.36M | -$95.47M | -$82.77M | -$68.38M | -$47.30M | -$57.84B | -$7.33M |
| Income Before Tax | -$24.97M | -$9.71M | -$7.72M | -$112.48M | -$98.04M | -$91.78M | -$69.24M | -$48.55M | -$83.97M | -$7.97M |
| Income Tax Expense | $2,000 | -$127,000 | $897,000 | $13.62M | $0 | $0 | $0 | $12,000 | $0 | $3,921 |
| Net Income? | -$24.97M | -$9.58M | -$8.62M | -$126.09M | -$98.04M | -$91.78M | -$69.24M | -$48.55M | -$83.97M | -$7.97M |
| EPS? | $-0.81 | $-0.83 | $-1.50 | $-26.92 | $-24.37 | $-28.94 | $-25.69 | $-18.43 | $-33.47 | $-8.11 |
| Diluted EPS? | $-0.81 | $-0.83 | $-1.50 | $-26.92 | $-24.37 | $-28.94 | $-25.69 | $-18.43 | $-33.47 | $-8.11 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality